Comparison of fasting human pancreatic polypeptide levels among patients with pancreatic ductal adenocarcinoma, chronic pancreatitis, and type 2 diabetes mellitus

Sajan Jiv Singh Nagpal, William R. Bamlet, Yogish C Kudva, Suresh T Chari

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives Human pancreatic polypeptide (HPP) is a hormone secreted by the ventral pancreas. While postprandial HPP levels have been studied in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC), there are limited data on fasting HPP in these diseases. Methods Fasting serum HPP was measured in the following groups of patients: CP with diabetes mellitus (DM) (n = 16), CP without DM (n = 34), PDAC with new-onset DM (n = 50), PDAC without DM (n = 49), new-onset type 2 DM (n = 50), and controls without DM (n = 49). Sixty-six had type 3c DM (CP with DM, n = 16; PDAC with new-onset DM, n = 50). Results Median fasting HPP levels (in picograms per milliliter) were similar among all groups. Median (interquartile range) HPP levels in new-onset type 2 DM (n = 50; 288.3 [80.1-1072.1]) were similar to those in type 3c DM (n = 66; 242.3 [64.9-890.9]) (P = 0.71). In PDAC (n = 99), HPP values were similar in pancreatic head (n = 75) versus body/tail (n = 24) tumors (245.3 [64.3-1091.3] vs 334.7 [136.1-841.5]; P = 0.95), regardless of DM. Conclusions Fasting HPP levels are similar in CP, PDAC, and controls regardless of glycemic status.

Original languageEnglish (US)
Pages (from-to)738-741
Number of pages4
JournalPancreas
Volume47
Issue number6
DOIs
StatePublished - Jul 1 2018

Fingerprint

Chronic Pancreatitis
Type 2 Diabetes Mellitus
Fasting
Diabetes Mellitus
Adenocarcinoma
human PPY protein
Pancreas
Hormones

Keywords

  • chronic pancreatitis
  • pancreatic cancer
  • pancreatic polypeptide
  • type 3c diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Comparison of fasting human pancreatic polypeptide levels among patients with pancreatic ductal adenocarcinoma, chronic pancreatitis, and type 2 diabetes mellitus. / Nagpal, Sajan Jiv Singh; Bamlet, William R.; Kudva, Yogish C; Chari, Suresh T.

In: Pancreas, Vol. 47, No. 6, 01.07.2018, p. 738-741.

Research output: Contribution to journalArticle

@article{7dca897ea3fb48739cc3c518c5edf427,
title = "Comparison of fasting human pancreatic polypeptide levels among patients with pancreatic ductal adenocarcinoma, chronic pancreatitis, and type 2 diabetes mellitus",
abstract = "Objectives Human pancreatic polypeptide (HPP) is a hormone secreted by the ventral pancreas. While postprandial HPP levels have been studied in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC), there are limited data on fasting HPP in these diseases. Methods Fasting serum HPP was measured in the following groups of patients: CP with diabetes mellitus (DM) (n = 16), CP without DM (n = 34), PDAC with new-onset DM (n = 50), PDAC without DM (n = 49), new-onset type 2 DM (n = 50), and controls without DM (n = 49). Sixty-six had type 3c DM (CP with DM, n = 16; PDAC with new-onset DM, n = 50). Results Median fasting HPP levels (in picograms per milliliter) were similar among all groups. Median (interquartile range) HPP levels in new-onset type 2 DM (n = 50; 288.3 [80.1-1072.1]) were similar to those in type 3c DM (n = 66; 242.3 [64.9-890.9]) (P = 0.71). In PDAC (n = 99), HPP values were similar in pancreatic head (n = 75) versus body/tail (n = 24) tumors (245.3 [64.3-1091.3] vs 334.7 [136.1-841.5]; P = 0.95), regardless of DM. Conclusions Fasting HPP levels are similar in CP, PDAC, and controls regardless of glycemic status.",
keywords = "chronic pancreatitis, pancreatic cancer, pancreatic polypeptide, type 3c diabetes mellitus",
author = "Nagpal, {Sajan Jiv Singh} and Bamlet, {William R.} and Kudva, {Yogish C} and Chari, {Suresh T}",
year = "2018",
month = "7",
day = "1",
doi = "10.1097/MPA.0000000000001077",
language = "English (US)",
volume = "47",
pages = "738--741",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Comparison of fasting human pancreatic polypeptide levels among patients with pancreatic ductal adenocarcinoma, chronic pancreatitis, and type 2 diabetes mellitus

AU - Nagpal, Sajan Jiv Singh

AU - Bamlet, William R.

AU - Kudva, Yogish C

AU - Chari, Suresh T

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Objectives Human pancreatic polypeptide (HPP) is a hormone secreted by the ventral pancreas. While postprandial HPP levels have been studied in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC), there are limited data on fasting HPP in these diseases. Methods Fasting serum HPP was measured in the following groups of patients: CP with diabetes mellitus (DM) (n = 16), CP without DM (n = 34), PDAC with new-onset DM (n = 50), PDAC without DM (n = 49), new-onset type 2 DM (n = 50), and controls without DM (n = 49). Sixty-six had type 3c DM (CP with DM, n = 16; PDAC with new-onset DM, n = 50). Results Median fasting HPP levels (in picograms per milliliter) were similar among all groups. Median (interquartile range) HPP levels in new-onset type 2 DM (n = 50; 288.3 [80.1-1072.1]) were similar to those in type 3c DM (n = 66; 242.3 [64.9-890.9]) (P = 0.71). In PDAC (n = 99), HPP values were similar in pancreatic head (n = 75) versus body/tail (n = 24) tumors (245.3 [64.3-1091.3] vs 334.7 [136.1-841.5]; P = 0.95), regardless of DM. Conclusions Fasting HPP levels are similar in CP, PDAC, and controls regardless of glycemic status.

AB - Objectives Human pancreatic polypeptide (HPP) is a hormone secreted by the ventral pancreas. While postprandial HPP levels have been studied in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC), there are limited data on fasting HPP in these diseases. Methods Fasting serum HPP was measured in the following groups of patients: CP with diabetes mellitus (DM) (n = 16), CP without DM (n = 34), PDAC with new-onset DM (n = 50), PDAC without DM (n = 49), new-onset type 2 DM (n = 50), and controls without DM (n = 49). Sixty-six had type 3c DM (CP with DM, n = 16; PDAC with new-onset DM, n = 50). Results Median fasting HPP levels (in picograms per milliliter) were similar among all groups. Median (interquartile range) HPP levels in new-onset type 2 DM (n = 50; 288.3 [80.1-1072.1]) were similar to those in type 3c DM (n = 66; 242.3 [64.9-890.9]) (P = 0.71). In PDAC (n = 99), HPP values were similar in pancreatic head (n = 75) versus body/tail (n = 24) tumors (245.3 [64.3-1091.3] vs 334.7 [136.1-841.5]; P = 0.95), regardless of DM. Conclusions Fasting HPP levels are similar in CP, PDAC, and controls regardless of glycemic status.

KW - chronic pancreatitis

KW - pancreatic cancer

KW - pancreatic polypeptide

KW - type 3c diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85049039344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049039344&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000001077

DO - 10.1097/MPA.0000000000001077

M3 - Article

C2 - 29771765

AN - SCOPUS:85049039344

VL - 47

SP - 738

EP - 741

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 6

ER -